Literature DB >> 28321711

Heparin induced thrombocytopenia with mechanical circulatory support devices: review of the literature and management considerations.

Jonathan Bain1,2, Alexander H Flannery3,4, Jeremy Flynn3,4, William Dager5,6,7,8.   

Abstract

Whether for temporary or long term use, mechanical circulatory support (MCS) has seen increased utilization and interest over the past several years. Even though these devices innately cause thrombocytopenia, co-administration of heparin anticoagulation carries the risk for heparin-induced thrombocytopenia (HIT). This poses challenges for practitioners as very few studies provide guidance for the management of this condition, particularly in this population. This has led to a wide spectrum of treatment protocols within current practice. This review was developed to bring together available literature on the management of HIT in patients with MCS along with practical experience and clinical opinion in order to help guide the management of these patients.

Entities:  

Keywords:  Direct thrombin inhibitors; ECLS; HIT; Heparin induced thrombocytopenia; MCS; Mechanical circulatory support

Mesh:

Substances:

Year:  2017        PMID: 28321711     DOI: 10.1007/s11239-017-1494-0

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  75 in total

1.  Vitamin K reduces bleeding in left ventricular assist device recipients.

Authors:  R J Kaplon; A M Gillinov; N G Smedira; K Kottke-Marchant; I W Wang; M Goormastic; P M McCarthy
Journal:  J Heart Lung Transplant       Date:  1999-04       Impact factor: 10.247

2.  Effectiveness of bivalirudin as a replacement for heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting.

Authors:  Andreas Koster; Bruce Spiess; Derek P Chew; Thomas Krabatsch; Luc Tambeur; Abe DeAnda; Roland Hetzer; Hermann Kuppe; Nicholas G Smedira; A Michael Lincoff
Journal:  Am J Cardiol       Date:  2004-02-01       Impact factor: 2.778

3.  Comparison of bivalirudin to lepirudin and argatroban in patients with heparin-induced thrombocytopenia.

Authors:  Jonathan Bain; Andrew Meyer
Journal:  Am J Health Syst Pharm       Date:  2015-09-01       Impact factor: 2.637

Review 4.  Antithrombotic potential of the contact activation pathway.

Authors:  Alvin H Schmaier
Journal:  Curr Opin Hematol       Date:  2016-09       Impact factor: 3.284

5.  Pericardial blood activates the extrinsic coagulation pathway during clinical cardiopulmonary bypass.

Authors:  J H Chung; N Gikakis; A K Rao; T A Drake; R W Colman; L H Edmunds
Journal:  Circulation       Date:  1996-06-01       Impact factor: 29.690

Review 6.  Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management.

Authors:  Eduard Shantsila; Gregory Y H Lip; Beng H Chong
Journal:  Chest       Date:  2009-06       Impact factor: 9.410

7.  Bioline heparin-coated ECMO with bivalirudin anticoagulation in a patient with acute heparin-induced thrombocytopenia: the immune reaction appeared to continue unabated.

Authors:  F Pappalardo; G Maj; A Scandroglio; F Sampietro; A Zangrillo; A Koster
Journal:  Perfusion       Date:  2009-03       Impact factor: 1.972

8.  Primary anticoagulation with bivalirudin for patients with implantable ventricular assist devices.

Authors:  Marina Pieri; Natalia Agracheva; Ambra Licia Di Prima; Teodora Nisi; Michele De Bonis; Francesca Isella; Alberto Zangrillo; Federico Pappalardo
Journal:  Artif Organs       Date:  2013-09-19       Impact factor: 3.094

9.  Successful use of bivalirudin for cardiopulmonary bypass in a patient with heparin allergy.

Authors:  F Pappalardo; A Franco; G Crescenzi; A Poli; A Zangrillo; A Koster
Journal:  Perfusion       Date:  2007-01       Impact factor: 1.972

10.  Nonclinical Safety Assessment of PER977: A Small Molecule Reversal Agent for New Oral Anticoagulants and Heparins.

Authors:  Dexter W Sullivan; Shayne C Gad; Bryan Laulicht; Sasha Bakhru; Solomon Steiner
Journal:  Int J Toxicol       Date:  2015-06-15       Impact factor: 2.032

View more
  1 in total

Review 1.  VV extracorporeal life support for the Third Millennium: will we need anticoagulation?

Authors:  Danny Eytan; Yuval Bitterman; Gail M Annich
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.